{
    "id": "correct_starring_00075_3",
    "rank": 95,
    "data": {
        "url": "https://quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8k-other-events-5607403",
        "read_more_link": "",
        "language": "en",
        "title": "Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Other Events",
        "top_image": "https://www.sec.gov/files/sec-logo.png",
        "meta_img": "https://www.sec.gov/files/sec-logo.png",
        "images": [
            "https://quantisnow.com/_next/static/media/logo.c16299ca.svg",
            "https://quantisnow.com/_next/static/media/logo_square.c56ad2f3.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "Biotechnology: Pharmaceutical Preparations",
            "Health Care",
            "VRPX",
            "Virpax Pharmaceuticals Inc."
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "UNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nFORM 8-K\n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934\n\nDate of Report (Date of earliest event reported):\n\nVirpax Pharmaceuticals, Inc.\n\n(Exact name of registrant as specified in its charter)\n\nDelaware 001-40064 82-1510982 (State or Other Jurisdiction\n\nof Incorporation) (Commission File Number)\n\n(I.R.S. Employer\n\nIdentification No.)\n\n1055 Westlakes Drive, Suite 300\n\nBerwyn, PA 19312\n\n(Address of principal executive offices, including zip code)\n\n(610) 727-4597\n\n(Registrant’s telephone number, including area code)\n\nN/A\n\n(Former name or former address, if changed since last report)\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of Each Class: Trading Symbol Name of Each Exchange on which Registered Common Stock, par value $0.00001 per share VRPX The Nasdaq Capital Market\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).\n\nEmerging growth company ☒\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nItem 8.01. Other Events.\n\nOn or about July 11, 2024, Virpax Pharmaceuticals, Inc. (the “Company”) issued an aggregate of 1,975,283 shares of its common stock to investors who exercised warrants previously issued by the Company. In connection with such exercise, the Company received proceeds of approximately $2,666,632. The number of shares of the Company’s common stock outstanding immediately after giving effect to these exercises was 4,813,181.\n\nThe issuance to investors of the shares of common stock upon exercise of the warrants was registered under a registration statement filed by the Company on Form S-1(File No. 333-278796), which was declared effective on May 14, 2024.\n\n1\n\nSignature\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nVIRPAX PHARMACEUTICALS, INC. Dated: July 15, 2024 By: /s/ Gerald Bruce Name: Gerald Bruce Title: Chief Executive Officer\n\n2"
    }
}